Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Summary

This is a multicentric, open-label,non-randomized concurrent control, 1:1 match,non-inferiority trial that assesses the efficacy and safety of neoadjuvant chemotherapy regimen DC-T and EC-T in breast cancer patients.

Conditions

• Breast Cancer

Interventions

DRUG

Pegylated liposomal doxorubicin

a new kind of doxorubicin

DRUG

Cyclophosphamide

traditional chemotherapy drug

DRUG

Epirubicin

traditional chemotherapy drug used in breast cancer

DRUG

Docetaxel

traditional chemotherapy drug used in breast cancer

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Women's Hospital School Of Medicine Zhejiang University

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Zhejiang Provincial People's Hospital

  collaborator OTHER

• Zhejiang Provincial Hospital of TCM

  collaborator OTHER

• First People's Hospital of Hangzhou

  collaborator OTHER

• Hangzhou Hospital of Traditional Chinese Medicine

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• Jinhua Central Hospital

  collaborator OTHER

• Zhejiang University

  lead OTHER

Principal Investigators

• Huang Jian, Dr · Second Affiliated Hospital of Zhejiang University School of Medicine

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-12-31

Primary Completion

2021-12-31

Completion

2021-12-31

Countries

• China

Study Locations